-+ 0.00%
-+ 0.00%
-+ 0.00%

TEVOGEN BIO SPECIALTY CARE REPORTS TOP-LINE REVENUE FORECAST OF NEARLY $1 BILLION IN LAUNCH YEAR AND CUMULATIVE 5-YEAR ESTIMATE BETWEEN $18 BILLION AND $22 BILLION

Reuters·10/21/2024 19:58:24

Please log in to view news